Is a complete BLRX research report available?

No complete published report is available for BioLineRx Ltd. (BLRX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

BioLineRx Ltd. (BLRX)

NASDAQ: BLRX · USD

$2.70

-0.05 (-1.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first BLRX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	12.8M
Revenue (ttm)	1.4M
Net income (ttm)	-7.9M
EPS (ttm)	-$0.00
Shares out	2.6B
Volume	7,123
Beta	0.62
Price target	$17.5	+548.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.4M
Net income (ttm): -7.9M
EPS (ttm): -$0.00
Market cap: 12.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All BLRX indicators

Market & fundamental data

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001498403
Company name	BioLineRx Ltd.
Country	Israel
Country code	US
Cusip	09071M304
Employees	24
Employees Change	-4%
Employees Change Percent	-14.29
Enterprise value	$8.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2011-07-25
Isin	US09071M3043
Last refreshed	2026-07-31
Market cap	$12.8M
Market cap category	Nano-Cap
Price	$2.7
Price currency	USD
Rev Per Employee	58,416.67x
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	BLRX
Website	https://www.biolinerx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-61.57%
EV Sales Forward	4.85x
EV/Sales	6.12x
FCF yield	-60.72%
P/B ratio	0.62x
P/S ratio	9.15x
PS Forward	7.25x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-1,178.38%
EBITDA Margin	-1,130.16%
Gross margin	79.24%
Gross Profit	$1.1M
Gross Profit Growth	-92.34%
Gross Profit Growth Q	72.85%
Net Income	$-7.9M
Net Income Growth Years	2%
Pretax Margin	-694.79%
Profit Per Employee	$-329,292
ROA	-16.55
Roa5y	-24.97
ROCE	-43.3
ROE	-46.72
Roe5y	-74.27
ROIC	-21.12

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-40.27%
Cagr15y	-37.54%
Cagr1y	-34.64%
Cagr3y	-63.85%
Cagr5y	-53.96%
EPS Growth Years	0
Revenue Growth	-93.72x
Revenue Growth Q	87.06x
Revenue Growth Quarters	1x
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.03
Assets	$38.8M
Cash	$17.4M
Current Assets	$21.6M
Current Liabilities	$13.6M
Debt	$9.1M
Debt Equity	$0.44
Equity	$20.8M
Interest Coverage	-10.08
Liabilities	$18M
Long Term Assets	$17.2M
Long Term Liabilities	$4.3M
Net Cash	$8.3M
Net Cash By Market Cap	$64.53
Net Cash Growth	-34.4%
Net Debt Equity	$-0.4
Tangible Book Value	$325,000
Tangible Book Value Per Share	$0
WACC	8.39

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.58
Inventory Turnover	0.11
Net Working Capital	$-4.7M
Quick ratio	1.41
Working Capital	$8M
Working Capital Turnover	$0.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-73.94%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.42%
1Y total return	-34.62%
200-day SMA	3.01
3Y total return	-95.28%
50-day SMA	3.11
50-day SMA vs 200-day SMA	50over200
5Y total return	-97.93%
All Time High	4,122
All Time High Change	-99.93%
All Time High Date	2012-01-24
All Time Low	2.15
All Time Low Change	25.58%
All Time Low Date	2026-04-01
ATR	0.19
Beta	0.62
Ch YTD	-2.53
High	2.77
High52	4.56
High52 Date	2025-10-07
High52ch	-40.79%
Low	2.68
Low52	2.15
Low52 Date	2026-04-01
Low52ch	25.58%
Ma50ch	-13.21%
Price vs 200-day SMA	-10.18%
RSI	34.94
RSI Monthly	33.12
RSI Weekly	43.06
Sharpe ratio	-0.46x
Sortino ratio	-0.59
Total Return	-73.94%
Tr YTD	-2.53
Tr15y	-99.91%
Tr1m	-12.9%
Tr1w	-5.59%
Tr3m	-12.05%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.24
Earnings Revenue Estimate	442,800x
Earnings Revenue Estimate Growth	45.66x
Operating Income	$-10.9M
Operating margin	-777.5
Price target	$17.5
Price Target Change	$548

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,508,325,990%
Float Percent	96.07%
Net Borrowing	-4,943,000
Shares Insiders	0.39%
Shares Institutions	3.31%
Shares Out	2,610,814,390
Shares Qo Q	-0.08%
Shares Yo Y	73.94%
Short Ratio	5.84
Short Shares	3.36

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-8.1M
Adjusted OCF	-8,043,000
Average Volume	20,659.85x
Bv Per Share	0.01
CAPEX	$-31,000
Ch10y	-99.42
Ch15y	-99.91
Ch1m	-12.9
Ch1w	-5.59
Ch1y	-34.62
Ch3m	-12.05
Ch3y	-95.28
Ch5y	-97.93
Ch6m	-14.83
Change	-1.82%
Change From Open	-1.82
Close	2.75
Days Gap	0
Depreciation Amortization	150,000
Dollar Volume	19,232.1
Earnings Date	2026-08-14
Earnings Time	bmo
EBIT	$-10.9M
EBITDA	$-10.5M
EPS	$-0
F Score	3
FCF	$-7.8M
FCF EV Yield	-90.76x
FCF Per Share	$-0
Financing CF	-1,746,000
Fiscal Year End	December
Founded	2,003
Investing CF	2,335,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-05-27
Last Report Date	2026-03-31
Last Split Date	2025-01-30
Last Split Type	Reverse
Last10k Filing Date	2026-03-23
Ma150	2.87
Ma150ch	-5.92%
Ma20	2.95
Ma20ch	-8.51%
Net CF	-6,532,000
Next Earnings Date	2026-08-13
Open	2.75
Optionable	Yes
Position In Range	22.22
Ppne	867,000
Price Date	2026-07-30
Ptbv Ratio	39.49
Relative Volume	0.34x
Revenue	1,402,000x
SBC By Revenue	19.97x
Share Based Comp	280,000
Tr6m	-14.83%
Volume	7,123
Z Score	-14.68

BioLineRx Ltd. (BLRX)

Coverage state: Market snapshot only — no published research

Generate the first BLRX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · BLRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BLRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on BLRX

Frequently asked questions